ABUS
Arbutus Biopharma Corp
4.70$
+4.9%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.0% | +4.1% | +6.5% | -12.2% | -6.2% | -11.2% | -11.7% | -5.4% | -3.2% | +192.9% | -1.1% | |
| – | -6.8% | +2.9% | +9.1% | -10.4% | -4.1% | -8.3% | -11.7% | -5.5% | -3.1% | +193.3% | -1.1% | |
| – | +49.9% | +64.0% | +45.7% | -49.3% | +14.1% | +2.1% | +0.9% | -40.1% | -19.6% | +31.6% | -19.1% | |
| – | -6.1% | +2.6% | +9.9% | -10.0% | -4.0% | -8.1% | -13.0% | -4.5% | -2.4% | +4.1% | -2.7% | |
| – | -35.9% | +20.4% | -3.4% | -22.2% | +49.8% | -50.9% | -13.3% | -11.7% | +93.0% | -24.9% | +13,599.8% | |
| – | – | – | -623,400,100.0% | – | – | – | – | – | – | – | – | |
| – | -2.3% | -7.1% | +5.4% | -10.7% | +2.4% | +10.2% | -46.4% | +0.1% | -11.2% | -5.8% | -10.0% | |
| – | +0.7% | -9.7% | +11.3% | -16.3% | -17.5% | +24.4% | -74.2% | +3.2% | +15.9% | -15.0% | -34.1% | |
| – | +3.2% | +18.1% | -9.8% | +3.3% | +3.2% | +16.6% | -8.7% | +3.3% | +3.0% | +15.4% | -18.5% | |
| – | +42.6% | +16.1% | -29.1% | -12.7% | +0.0% | -3.3% | -41.0% | -23.5% | +16.0% | +24.6% | +94.9% | |
| – | -11.2% | +8.1% | +6.8% | -12.7% | -8.9% | -18.7% | +4.8% | -6.7% | -1.1% | +239.8% | -0.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.6% | +4.3% | +7.1% | +0.5% | +0.5% | +0.4% | +0.9% | -0.3% | -0.1% | +1.9% | +1.2% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.